OPKO Health (NASDAQ:OPK) Now Covered by JPMorgan Chase & Co.

Stock analysts at JPMorgan Chase & Co. initiated coverage on shares of OPKO Health (NASDAQ:OPK - Get Free Report) in a report issued on Friday, MarketBeat.com reports. The firm set a "neutral" rating on the biotechnology company's stock.

Other research analysts also recently issued reports about the company. Barrington Research reiterated an "outperform" rating and set a $2.25 target price on shares of OPKO Health in a research report on Wednesday, March 12th. StockNews.com upgraded OPKO Health from a "sell" rating to a "hold" rating in a research report on Monday, March 3rd. Finally, HC Wainwright reissued a "buy" rating and set a $3.00 target price on shares of OPKO Health in a research report on Monday, April 7th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $2.75.

OPKO Health Price Performance

Shares of NASDAQ OPK remained flat at $1.41 during mid-day trading on Friday. The stock had a trading volume of 2,031,482 shares, compared to its average volume of 3,896,295. The firm's 50 day simple moving average is $1.64 and its two-hundred day simple moving average is $1.57. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30. OPKO Health has a 1 year low of $1.15 and a 1 year high of $2.04. The company has a market cap of $946.89 million, a price-to-earnings ratio of -7.42 and a beta of 1.78.

OPKO Health (NASDAQ:OPK - Get Free Report) last released its earnings results on Thursday, February 27th. The biotechnology company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.08) by $0.09. The firm had revenue of $183.60 million for the quarter, compared to the consensus estimate of $155.42 million. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. Analysts anticipate that OPKO Health will post -0.25 EPS for the current fiscal year.

Insider Activity

In other news, CEO Phillip Md Et Al Frost acquired 47,537 shares of the business's stock in a transaction dated Tuesday, January 28th. The shares were purchased at an average price of $1.47 per share, with a total value of $69,879.39. Following the transaction, the chief executive officer now directly owns 213,234,014 shares in the company, valued at approximately $313,454,000.58. This represents a 0.02 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last 90 days, insiders have bought 814,971 shares of company stock worth $1,308,192. Company insiders own 49.69% of the company's stock.

Institutional Trading of OPKO Health

A number of institutional investors have recently made changes to their positions in the business. Millennium Management LLC boosted its stake in OPKO Health by 85.3% in the 4th quarter. Millennium Management LLC now owns 4,588,526 shares of the biotechnology company's stock worth $6,745,000 after purchasing an additional 2,112,382 shares in the last quarter. Lazard Asset Management LLC raised its holdings in shares of OPKO Health by 143.6% in the fourth quarter. Lazard Asset Management LLC now owns 2,548,667 shares of the biotechnology company's stock worth $3,746,000 after buying an additional 1,502,342 shares during the last quarter. Altshuler Shaham Ltd acquired a new stake in shares of OPKO Health during the fourth quarter worth $2,082,000. Norges Bank purchased a new stake in shares of OPKO Health during the fourth quarter valued at $1,657,000. Finally, Two Sigma Investments LP lifted its position in OPKO Health by 136.1% during the 4th quarter. Two Sigma Investments LP now owns 1,647,567 shares of the biotechnology company's stock worth $2,422,000 after acquiring an additional 949,671 shares during the period. Institutional investors and hedge funds own 64.63% of the company's stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.